These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 10529242)

  • 1. Kinetics and thermodynamics of dimer formation and dissociation for a recombinant humanized monoclonal antibody to vascular endothelial growth factor.
    Moore JM; Patapoff TW; Cromwell ME
    Biochemistry; 1999 Oct; 38(42):13960-7. PubMed ID: 10529242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen.
    Chen Y; Wiesmann C; Fuh G; Li B; Christinger HW; McKay P; de Vos AM; Lowman HB
    J Mol Biol; 1999 Nov; 293(4):865-81. PubMed ID: 10543973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor.
    Lin YS; Nguyen C; Mendoza JL; Escandon E; Fei D; Meng YG; Modi NB
    J Pharmacol Exp Ther; 1999 Jan; 288(1):371-8. PubMed ID: 9862791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and concentration-response of murine anti-VEGF monoclonal antibody in tumor-bearing mice and extrapolation to humans.
    Mordenti J; Thomsen K; Licko V; Chen H; Meng YG; Ferrara N
    Toxicol Pathol; 1999; 27(1):14-21. PubMed ID: 10367667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antioxidants for prevention of methionine oxidation in recombinant monoclonal antibody HER2.
    Lam XM; Yang JY; Cleland JL
    J Pharm Sci; 1997 Nov; 86(11):1250-5. PubMed ID: 9383735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer.
    Gordon MS; Margolin K; Talpaz M; Sledge GW; Holmgren E; Benjamin R; Stalter S; Shak S; Adelman D
    J Clin Oncol; 2001 Feb; 19(3):843-50. PubMed ID: 11157038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversible self-association increases the viscosity of a concentrated monoclonal antibody in aqueous solution.
    Liu J; Nguyen MD; Andya JD; Shire SJ
    J Pharm Sci; 2005 Sep; 94(9):1928-40. PubMed ID: 16052543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders.
    Presta LG; Chen H; O'Connor SJ; Chisholm V; Meng YG; Krummen L; Winkler M; Ferrara N
    Cancer Res; 1997 Oct; 57(20):4593-9. PubMed ID: 9377574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Construction of anti-human VEGF165 chimeric antibodies and expression in eukaryotic cells].
    Ran Y; Yang Z; Wang G
    Zhonghua Zhong Liu Za Zhi; 1999 Nov; 21(6):412-5. PubMed ID: 11776613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies.
    Kim KJ; Li B; Houck K; Winer J; Ferrara N
    Growth Factors; 1992; 7(1):53-64. PubMed ID: 1380254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration.
    Mordenti J; Cuthbertson RA; Ferrara N; Thomsen K; Berleau L; Licko V; Allen PC; Valverde CR; Meng YG; Fei DT; Fourre KM; Ryan AM
    Toxicol Pathol; 1999; 27(5):536-44. PubMed ID: 10528633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors.
    Sweeney CJ; Miller KD; Sissons SE; Nozaki S; Heilman DK; Shen J; Sledge GW
    Cancer Res; 2001 Apr; 61(8):3369-72. PubMed ID: 11309294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fidelity of binding of the guanidinium nucleic acid (DNG) d(Tg)4-T-azido with short strand DNA oligomers (A5G3A5, GA4G3A4G, G2A3G3A3G2, G2A2G5A2G2). A kinetic and thermodynamic study.
    Blaskó A; Minyat EE; Dempcy RO; Bruice TC
    Biochemistry; 1997 Jun; 36(25):7821-31. PubMed ID: 9201925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinetic characterization of the pH-dependent oligomerization of R67 dihydrofolate reductase.
    Méjean A; Bodenreider C; Schuerer K; Goldberg ME
    Biochemistry; 2001 Jul; 40(27):8169-79. PubMed ID: 11434787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversible NaCl-induced aggregation of a monoclonal antibody at low pH: Characterization of aggregates and factors affecting aggregation.
    Bickel F; Herold EM; Signes A; Romeijn S; Jiskoot W; Kiefer H
    Eur J Pharm Biopharm; 2016 Oct; 107():310-20. PubMed ID: 27449627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Construction and expression of single-chain Fv antibody against human VEGF].
    Wang D; Yang X; Yuan Q
    Zhonghua Yi Xue Za Zhi; 2000 Jul; 80(7):526-9. PubMed ID: 11798812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data.
    Margolin K; Gordon MS; Holmgren E; Gaudreault J; Novotny W; Fyfe G; Adelman D; Stalter S; Breed J
    J Clin Oncol; 2001 Feb; 19(3):851-6. PubMed ID: 11157039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions.
    Lee CG; Heijn M; di Tomaso E; Griffon-Etienne G; Ancukiewicz M; Koike C; Park KR; Ferrara N; Jain RK; Suit HD; Boucher Y
    Cancer Res; 2000 Oct; 60(19):5565-70. PubMed ID: 11034104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The alternatively folded state of the antibody C(H)3 domain.
    Thies MJ; Kammermeier R; Richter K; Buchner J
    J Mol Biol; 2001 Jun; 309(5):1077-85. PubMed ID: 11399080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specific ion and buffer effects on protein-protein interactions of a monoclonal antibody.
    Roberts D; Keeling R; Tracka M; van der Walle CF; Uddin S; Warwicker J; Curtis R
    Mol Pharm; 2015 Jan; 12(1):179-93. PubMed ID: 25389571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.